[Back to Issue 8 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]
[View Full Article] [Download Reprint (PDF)]

Targeted Delivery of Doxorubicin: Drug Delivery System Based on PAMAM Dendrimers

N. G. Yabbarov1*, G. A. Posypanova2, E. A. Vorontsov3, O. N. Popova2, and E. S. Severin3

1Bioengineering Center, Russian Academy of Sciences, pr. 60-letiya Oktyabrya 7/1, 117312 Moscow, Russia; fax: (499) 613-4818; E-mail: nikita_yabbarov@yahoo.com

2National Research Center “Kurchatov Institute”, pl. Akademika Kurchatova 1, 123182 Moscow, Russia; fax: (499) 196-1704

3Russian Research Center of Molecular Diagnostics and Therapy, Simferopolsky Bulvar 8, 117149 Moscow, Russia; fax: (499) 613-2633

* To whom correspondence should be addressed.

Received November 27, 2012; Revision received March 13, 2013
Polyamidoamine (PAMAM) dendrimers of the second generation (G2) are branched polymers containing 16 surface amino groups that allow them to be used as universal carriers on creating systems for drug delivery. G2 labeled with fluorescein isothiocyanate (FITC) efficiently bound with the surface of tumor cells at 4°C and was absorbed by the cells at 37°C. The covalent binding to G2-FITC of a vector protein, a recombinant fragment of the human alpha-fetoprotein receptor-binding domain (rAFP3D), increased the binding and endocytosis efficiency more than threefold. Covalent conjugates of G2 with doxorubicin (Dox) obtained by acid-labile linking of cis-aconitic anhydride (CAA) without the vector protein (G2-Dox) and with the vector protein rAFP3D (rAFP3D-G2-Dox) were accumulated by the tumor cells with high efficiency. However, a selective effect was observed only in rAFP3D-G2-Dox, which also demonstrated high cytotoxic activity against the human ovarian adenocarcinoma SKOV3 cells and low cytotoxicity against human peripheral blood lymphocytes. Based on these results, rAFP3D-G2 conjugate is promising for selective delivery of antitumor drugs.
KEY WORDS: dendrimers, targeted drug delivery, endocytosis, alpha-fetoprotein, acid-labile linker, antitumor

DOI: 10.1134/S000629791308004X